Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Lyell Immunopharma's Accounts Payables fell 2858.73% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2858.73%. This contributed to the annual value of $5.4 million for FY2024, which is 1139.71% up from last year.
  • Per Lyell Immunopharma's latest filing, its Accounts Payables stood at $2.6 million for Q3 2025, which was down 2858.73% from $3.4 million recorded in Q2 2025.
  • Lyell Immunopharma's Accounts Payables' 5-year high stood at $6.5 million during Q1 2022, with a 5-year trough of $2.6 million in Q3 2025.
  • In the last 5 years, Lyell Immunopharma's Accounts Payables had a median value of $4.3 million in 2022 and averaged $4.4 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Accounts Payables crashed by 6586.85% in 2021, and later skyrocketed by 3668.47% in 2023.
  • Lyell Immunopharma's Accounts Payables (Quarter) stood at $3.2 million in 2021, then increased by 22.14% to $3.9 million in 2022, then rose by 22.98% to $4.8 million in 2023, then increased by 11.4% to $5.4 million in 2024, then plummeted by 52.14% to $2.6 million in 2025.
  • Its Accounts Payables was $2.6 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.7 million in Q1 2025.